메뉴 건너뛰기




Volumn 9, Issue 2, 2014, Pages

Correction: Circulating Ang-2 Mrna expression levels: Looking ahead to a new prognostic factor for NSCLC (PLoS ONE (2014) 9, 2 (e90009) DOI: 10.1371/journal.pone.0090009);Circulating ang-2 mrna expression levels: Looking ahead to a new prognostic factor for NSCLC

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; MESSENGER RNA;

EID: 84896532455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097979     Document Type: Erratum
Times cited : (13)

References (28)
  • 1
    • 84882977045 scopus 로고    scopus 로고
    • Genetics and biomarkers in personalisation of lung cancer treatment
    • Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382: 720-731.
    • (2013) Lancet , vol.382 , pp. 720-731
    • Rosell, R.1    Bivona, T.G.2    Karachaliou, N.3
  • 2
    • 84883013481 scopus 로고    scopus 로고
    • Management of nonsmall-cell lung cancer: Recent developments
    • Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of nonsmall-cell lung cancer: recent developments. Lancet 382: 709-719.
    • (2013) Lancet , vol.382 , pp. 709-719
    • Reck, M.1    Heigener, D.F.2    Mok, T.3    Soria, J.C.4    Rabe, K.F.5
  • 3
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
    • (2000) Nature , vol.407 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 4
    • 73649112748 scopus 로고    scopus 로고
    • Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels
    • Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, et al. (2009) Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175: 2159-2170.
    • (2009) Am J Pathol , vol.175 , pp. 2159-2170
    • Falcon, B.L.1    Hashizume, H.2    Koumoutsakos, P.3    Chou, J.4    Bready, J.V.5
  • 5
    • 84875456598 scopus 로고    scopus 로고
    • Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy
    • Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE (2013) Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73: 1649-1657.
    • (2013) Cancer Res , vol.73 , pp. 1649-1657
    • Gerald, D.1    Chintharlapalli, S.2    Augustin, H.G.3    Benjamin, L.E.4
  • 6
    • 84868486023 scopus 로고    scopus 로고
    • Angiopoietins in angiogenesis
    • Fagiani E, Christofori G (2013) Angiopoietins in angiogenesis. Cancer Lett 328: 18-26.
    • (2013) Cancer Lett , vol.328 , pp. 18-26
    • Fagiani, E.1    Christofori, G.2
  • 7
    • 60549103097 scopus 로고    scopus 로고
    • Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth
    • Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, et al. (2009) Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
    • (2009) Cancer Res , vol.69 , pp. 1324-1333
    • Nasarre, P.1    Thomas, M.2    Kruse, K.3    Helfrich, I.4    Wolter, V.5
  • 8
    • 84861820220 scopus 로고    scopus 로고
    • Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
    • Felcht M, Luck R, Schering A, Seidel P, Srivastava K, et al. (2012) Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122: 1991-2005.
    • (2012) J Clin Invest , vol.122 , pp. 1991-2005
    • Felcht, M.1    Luck, R.2    Schering, A.3    Seidel, P.4    Srivastava, K.5
  • 9
    • 84890667775 scopus 로고    scopus 로고
    • Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent anti-tumor, anti-angiogenic, and anti-metastatic efficacy
    • Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, et al. (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent anti-tumor, anti-angiogenic, and anti-metastatic efficacy. Clin Cancer Res.
    • (2013) Clin Cancer Res
    • Kienast, Y.1    Klein, C.2    Scheuer, W.3    Raemsch, R.4    Lorenzon, E.5
  • 10
    • 60749096085 scopus 로고    scopus 로고
    • Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
    • Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177.
    • (2009) Nat Rev Mol Cell Biol , vol.10 , pp. 165-177
    • Augustin, H.G.1    Koh, G.Y.2    Thurston, G.3    Alitalo, K.4
  • 11
    • 79956068289 scopus 로고    scopus 로고
    • Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2
    • Andersen S, Donnem T, Al-Shibli K, Al-Saad S, Stenvold H, et al. (2011) Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. PLoS One 6: e19773.
    • (2011) PLoS One , vol.6
    • Andersen, S.1    Donnem, T.2    Al-Shibli, K.3    Al-Saad, S.4    Stenvold, H.5
  • 12
    • 68849097805 scopus 로고    scopus 로고
    • Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy
    • Naumnik W, Chyczewska E, Ossolinska M (2009) Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy. Cancer Invest 27: 741-746.
    • (2009) Cancer Invest , vol.27 , pp. 741-746
    • Naumnik, W.1    Chyczewska, E.2    Ossolinska, M.3
  • 13
    • 84881060020 scopus 로고    scopus 로고
    • Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: A bronchoalveolar lavage and serum study
    • Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2013) Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol 788: 341-348.
    • (2013) Adv Exp Med Biol , vol.788 , pp. 341-348
    • Naumnik, W.1    Naumnik, B.2    Niewiarowska, K.3    Ossolinska, M.4    Chyczewska, E.5
  • 14
    • 34447525629 scopus 로고    scopus 로고
    • Serum angiopoietin-2 as a clinical marker for lung cancer
    • Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, et al. (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132: 200-206.
    • (2007) Chest , vol.132 , pp. 200-206
    • Park, J.H.1    Park, K.J.2    Kim, Y.S.3    Sheen, S.S.4    Lee, K.S.5
  • 15
    • 16644376056 scopus 로고    scopus 로고
    • Overexpression of Ang-2 mRNA in non-small cell lung cancer: Association with angiogenesis and poor prognosis
    • Takanami I (2004) Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep 12: 849-853.
    • (2004) Oncol Rep , vol.12 , pp. 849-853
    • Takanami, I.1
  • 17
    • 0035710746 scopus 로고    scopus 로고
    • -ΔΔCT method
    • DOI 10.1006/meth.2001.1262
    • Livak KJ, and Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 22DDCT Method. Methods 25:402-408 (Pubitemid 34164012)
    • (2001) Methods , vol.25 , Issue.4 , pp. 402-408
    • Livak, K.J.1    Schmittgen, T.D.2
  • 18
    • 33847056277 scopus 로고    scopus 로고
    • Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-A review of the literature
    • Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, et al. (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 12: 201-210.
    • (2007) Oncologist , vol.12 , pp. 201-210
    • Araujo, A.1    Ribeiro, R.2    Azevedo, I.3    Coelho, A.4    Soares, M.5
  • 20
    • 84855168417 scopus 로고    scopus 로고
    • Adjuvant chemotherapy for resected non-small-cell lung cancer: Future perspectives for clinical research
    • Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, et al. (2011) Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res 30: 115.
    • (2011) J Exp Clin Cancer Res , vol.30 , pp. 115
    • Bonomi, M.1    Pilotto, S.2    Milella, M.3    Massari, F.4    Cingarlini, S.5
  • 21
    • 84875937242 scopus 로고    scopus 로고
    • Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies
    • Li T, Kung HJ, Mack PC, Gandara DR (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31: 1039-1049.
    • (2013) J Clin Oncol , vol.31 , pp. 1039-1049
    • Li, T.1    Kung, H.J.2    Mack, P.C.3    Gandara, D.R.4
  • 22
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
    • (2010) N Engl J Med , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3    Shaw, A.T.4    Solomon, B.5
  • 23
    • 84887257904 scopus 로고    scopus 로고
    • Targeting angiogenesis in advanced non-small cell lung cancer
    • Lammers PE, Horn L (2013) Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw 11: 1235-1247.
    • (2013) J Natl Compr Canc Netw , vol.11 , pp. 1235-1247
    • Lammers, P.E.1    Horn, L.2
  • 24
    • 84874095390 scopus 로고    scopus 로고
    • Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab
    • Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, et al. (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19: 929-937.
    • (2013) Clin Cancer Res , vol.19 , pp. 929-937
    • Hegde, P.S.1    Jubb, A.M.2    Chen, D.3    Li, N.F.4    Meng, Y.G.5
  • 25
    • 84873545836 scopus 로고    scopus 로고
    • A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and antiangiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors
    • Thomas M, Kienast Y, Scheuer W, Bahner M, Kaluza K, et al. (2013) A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and antiangiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PLoS One 8: e54923.
    • (2013) PLoS One , vol.8
    • Thomas, M.1    Kienast, Y.2    Scheuer, W.3    Bahner, M.4    Kaluza, K.5
  • 26
    • 84896497658 scopus 로고    scopus 로고
    • A phase i first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies
    • KP P, NG C, A P, L A, AS L, et al. (2011) A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology 29.
    • (2011) Journal of Clinical Oncology , pp. 29
    • Kp, P.1    Ng, C.2    As, L.3
  • 27
    • 84863138369 scopus 로고    scopus 로고
    • A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization
    • Palmer GM, Tiran Z, Zhou Z, Capozzi ME, Park W, et al. (2012) A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. Br J Pharmacol 165: 1891-1903.
    • (2012) Br J Pharmacol , vol.165 , pp. 1891-1903
    • Palmer, G.M.1    Tiran, Z.2    Zhou, Z.3    Capozzi, M.E.4    Park, W.5
  • 28
    • 80053463397 scopus 로고    scopus 로고
    • A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis
    • Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, et al. (2011) A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation 18: 598-607.
    • (2011) Microcirculation , vol.18 , pp. 598-607
    • Rennel, E.S.1    Regula, J.T.2    Harper, S.J.3    Thomas, M.4    Klein, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.